ASP-3026- resistant ALK mutants don't bind ASP-3026

Stable Identifier
R-HSA-9700646
Type
Reaction [transition]
Species
Homo sapiens
Compartment
cytosol, plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
ASP-3026- resistant ALK mutants don't bind ASP-3026
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The following ALK mutants are resistant to inhibition by ASP-3026:

ALK T1551M: Amin et al 2016
ALK I1171S: Amin et al 2016
ALK I1171T: Katayama et al, 2014
ALK F1174L: Amin et al, 2016 (moderate)
ALKR 1192P: Amin et al, 2016
ALK G1269A: Amin et al, 2016 (moderate)
Literature References
PubMed ID Title Journal Year
25228534 Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

Katayama, R, Friboulet, L, Koike, S, Lockerman, EL, Khan, TM, Gainor, JF, Iafrate, AJ, Takeuchi, K, Taiji, M, Okuno, Y, Fujita, N, Engelman, JA, Shaw, AT

Clin Cancer Res 2014
27009859 TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors

Amin, AD, Li, L, Rajan, SS, Gokhale, V, Groysman, MJ, Pongtornpipat, P, Tapia, EO, Wang, M, Schatz, JH

Oncotarget 2016
Participants
Input
Participates
as an event of
Normal reaction
Liganded-ALK dimer binds type I ALK-binding TKIs (Homo sapiens)
Functional status

Loss of function of ASP3026-resistant ALK mutants [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Mondo
Authored
Rothfels, K  (2021-03-22)
Reviewed
Inghirami, G  (2021-05-04)
Created
Rothfels, K  (2020-09-16)
Cite Us!